Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Articles Tagged With: pharmacotherapy

  • Chronic Obstructive Pulmonary Disease Update for Primary Care Providers

    The Global Initiative for Chronic Obstructive Lung Disease 2023 report defines chronic obstructive pulmonary disease (COPD) as a heterogeneous lung condition characterized by chronic respiratory symptoms (dyspnea, cough, sputum production, and/or exacerbations) caused by abnormalities of the airways (bronchitis, bronchiolitis) and/or alveoli (emphysema) that result in persistent, often progressive, airflow obstruction. COPD was the fourth leading cause of death in the United States in 2018 and is estimated to be responsible for 3 million deaths annually around the world, with expected increases to 5.4 million annual deaths from COPD and related conditions by 2060.

  • Statins Plus Ezetimibe vs. Statins Alone

    A comparison of rosuvastatin 10 mg/day plus ezetimibe (10 mg/day) to 20 mg/day of rosuvastatin alone showed non-inferiority in three-year major cardiovascular outcomes, with lower LDL cholesterol levels and fewer episodes of drug discontinuation or dose reductions in the combination therapy group.

  • Hypertension in Adults: An Update

    Hypertension remains the leading cause of death and disability-adjusted life years globally, accounting for 10.4 million deaths per year. In the United States, hypertension accounts for more cardiovascular disease deaths than any other modifiable risk factor and is second only to cigarette smoking as a preventable cause of death for any reason.

  • Pharmacotherapy Considerations for COVID-19

    A summary of selected pharmacotherapy options proposed to treat COVID-19.

  • Statins, Blood Pressure, Cholesterol, and the Quest for a Healthy Lifestyle

    Debate continues about whether treating high blood pressure and cholesterol with pharmacotherapy stands in the way of patients making meaningful health choices.

  • Update in Treating Neuropathic Pain

    In an exhaustive review of the literature with a meta-analysis, the following medications were found to be most efficacious in the treatment of neuropathic pain: gabapentin, pregabalin, serotonin-noradrenaline reuptake inhibitors including duloxetine or venlafaxine, and tricyclic antidepressants.